Navigation Links
Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
Date:12/10/2008

SAN CARLOS, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced positive results from the Phase 1 trial of recombinant, secreted protein, NU206, the company's lead compound from its Wnt Therapeutics Program. This single-center, double-blind, placebo-controlled, single-ascending dose (SAD) trial tested the safety, tolerance and pharmacokinetics of a single intravenous (IV) administration of NU206, in 32 healthy male volunteers. Participants were enrolled in four cohorts of varying doses, with a maximum dose of 0.20 mg/kg/day. NU206 had a favorable safety profile, no serious adverse events were observed, and pharmacokinetics were predictable.

"Based on preclinical studies, we believe that NU206 promotes cell growth and repair, and, based also on results from this Phase 1 trial, believe it has the potential to offer a novel approach for the treatment of serious medical conditions such as gastrointestinal (GI) injury, inflammatory bowel disease, and bone disease," said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. "Because Nuvelo is in the process of merging with ARCA biopharma to create a cardiovascular-focused company, we are currently evaluating partnership and out-licensing opportunities for NU206 to continue development of the compound."

About NU206

NU206 (R-spondin1) is a recombinant, secreted protein that acts as a key regulator of the Wnt pathway, the critical pathway that stimulates cell growth and differentiation during homeostasis and pathogenesis in specific tissues including the GI epithelium and bone. Preclinical studies suggest it can promote growth and repair in animal models of radiation or cancer chemotherapy induced GI injury, inflammatory bowel disease, and bone disease.

About Nuvelo and Kyowa Hakko Kirin's Joint Collaborati
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
2. Nuvelo Reports Second Quarter 2008 Financial Results
3. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
4. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
5. Nuvelo and ARCA biopharma Advance Toward Completion of Merger
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014   BioTE ... therapy using natural, bio-identical hormone pellets, today announced ... MD to the company.   Dr. Rouzier is joining ... physician.      Dr. Rouzier was residency ... UCLA and is a board certified emergency physician ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 The ... clear and concise visual representation of history, migration, and ... was always regaled by family history stories stemming from ... as the "old country." Pictures and 8mm home movies ... side of the family, and Steve ordered a test ...
(Date:7/22/2014)... SHENZHEN , Cina, 22 luglio 2014 ... di BGI, la maggiore organizzazione di genomica del mondo, ... di sequenziamento dell,intero esoma umano con base la piattaforma ... Complete Genomics, molto apprezzata nel settore per essere in ... 99.999% di precisione e una rilevazione altamente sensibile di ...
(Date:7/22/2014)...  Semler Scientific, Inc. (Nasdaq: SMLR ... that develops patented products that assist healthcare providers ... announced that it will report second quarter 2014 ... markets on July 25, 2014. Doug Murphy-Chutorian, M.D., chief executive ... at 11 a.m. EDT, July 25, 2014. The ...
Breaking Biology Technology:Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2
... ... heat transfer fluid is a thermally stable, economical and high-performance solution for operations with ... ... new Paratherm GLT™ heat transfer fluid is a thermally stable, economical and high-performance solution ...
... , , , PHILADELPHIA ... Citation Laureates -- researchers likely to be in contention for Nobel honors -- ... economics to be announced from October 5-12. , , ... predictions of Nobel Prize winners. , , Each ...
... , PASADENA, Calif., Sept. 23 Alexandria ... today that it is commencing an underwritten public offering of ... and UBS Investment Bank are acting as joint bookrunning managers ... Equities, Inc. expects to grant the underwriters a thirty-day option ...
Cached Biology Technology:Paratherm's New GLT Heat Transfer Fluid: Thermally Stable & Lower Minimum Startup Temperatures 2Thomson Reuters Predicts Nobel Laureates 2Thomson Reuters Predicts Nobel Laureates 3Thomson Reuters Predicts Nobel Laureates 4Thomson Reuters Predicts Nobel Laureates 5Thomson Reuters Predicts Nobel Laureates 6Alexandria Real Estate Equities, Inc. Announces Public Follow-on Offering of 3,000,000 Shares of Common Stock 2Alexandria Real Estate Equities, Inc. Announces Public Follow-on Offering of 3,000,000 Shares of Common Stock 3
(Date:7/22/2014)... research team from the National Institute of Standards ... has demonstrated a dramatically improved technique for analyzing ... vibration "signatures." The new NIST technique is an ... spectroscopy, but one that delivers signals that are ... scattering, and 100 times stronger than obtained from ...
(Date:7/22/2014)... negative reputation as disease causing agents, some viruses ... help to shape the world we live in ... American Academy of Microbiology. , "Viruses participate in ... on the planet, from contributing to biogeochemical cycles, ... events," states Marilyn Roossinck of Pennsylvania State University, ...
(Date:7/22/2014)... much promise for treating damaged organs and tissues, but ... limiting their effectiveness. New methods are being developed and ... function after transplantation, as described in a Review article ... from Mary Ann Liebert, Inc., publishers. The article is ... website . , In the article ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Report on viruses looks beyond disease 2
... Going about their day-to-day business, bees have no need ... when Adrian Dyer from Monash University trained the fascinating insects ... they seemed to be able to do just that. But ... that the bees weren,t learning to recognise people. ,Because the ...
... Va. New advances for the detection of cancer ... Forest School of Biomedical Engineering and Science (SBES) are ... 2010 Royal Society of Chemistry,s magazine, " Lab on ... microfluidics. http://www.rsc.org/Publishing/Journals/lc/index.asp Microfluidics is the behavior ...
... deadline of February 4th is only one week ... most important international osteoporosis meeting of the year, ... abstract online:, http://www.iofwco-ecceo10.org/abstracts/ Abstracts ... Osteoporosis International, with opportunity for poster presentation. Authors ...
Cached Biology News:Bees recognize human faces using feature configuration 2Bees recognize human faces using feature configuration 3Advances in cancer detection research by Virginia Tech engineer featured in British magazine 2Advances in cancer detection research by Virginia Tech engineer featured in British magazine 3
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
... human cardiac troponin subunit T, a 31kDa protein ... contraction of cardiac muscle. It reacts with subunit ... It also cross-reacts with human skeletal troponin T ... Highly purified human cardiac troponin T ...
... is pleased to offer the ATTO-TAG ... detection of primary amines. Developed by ... the ATTO-TAG reagents are similar to ... (NDA) and anthracene-2,3-dicarboxaldehyde, all of which ...
Biology Products: